SAN DIEGO, Feb. 5, 2018 — Medical Marijuana, Inc. (OTC:MJNA), the first publicly traded cannabis company in the United States, today announced that its subsidiary HempMeds® garnered national news coverage with a feature story in the leading hemp industry publication Hemp Magazine.
A Jan. 29, 2018 article on Hemp Magazine’s website entitled “Titan Titus: An Interview With the HempMeds CEO” takes a deep dive into the story behind Dr. Stuart Titus, CEO of Medical Marijuana, Inc. and HempMeds®, HempMeds’® unique history and the cannabidiol (CBD) hemp oil industry. The article also discusses the Company’s journey to become the first-ever company to receive historic federal government import approvals for its CBD products in the nations of Brazil, Mexico and Paraguay.
HempMeds® was the first company to ever bring hemp-based CBD oil products to market in the U.S. and make CBD products available in bulk. Its flagship product, Real Scientific Hemp Oil™ (RSHO™), is available in 50 states and in 40 countries throughout the world.
“We’re thrilled to have had the opportunity to tell our story in such detail and help people feel more connected to the Company and the brand,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “This kind of media coverage helps us showcase our many accomplishments and explain how much we care about advocating for global access to CBD.”
About Medical Marijuana, Inc.
We are a company of firsts®. Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.
To see Medical Marijuana, Inc.’s corporate video, click here.
Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.’s shop.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
Public Relations Contact:
Chief Executive Officer CMW Media